Concentration of hs-Troponin in small cohort of transgender patients

•Little is known about the impact of sex-hormone therapy on hs-Tn in transgender patients.•Mean hs-Tn concentrations were similar in transgender women and transgender men, though analysis was limited by small sample size.•Further study on this vulnerable population underrepresented in troponin resea...

Full description

Saved in:
Bibliographic Details
Published inClinica chimica acta Vol. 539; pp. 66 - 69
Main Authors Boone, Stephen, Peacock, W. Frank, Wu, Alan H.B., Jaffe, Allan, Christenson, Robert H., Ettner, Frederic M., Dadkhah, Shahriar
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 15.01.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:•Little is known about the impact of sex-hormone therapy on hs-Tn in transgender patients.•Mean hs-Tn concentrations were similar in transgender women and transgender men, though analysis was limited by small sample size.•Further study on this vulnerable population underrepresented in troponin research is needed. Sex-differences in high sensitivity troponin (hs-Tn) concentrations are well established. There is, however, limited data to guide interpretation of hs-Tn in transgender patients, particularly those receiving gender-affirming hormone therapy. Our purpose was to evaluate troponin testing in transgender patients. Transgender adults attending a routine clinic visit provided demographic data, medical history, and venous blood samples. Patients with congestive heart failure or chronic kidney disease were excluded. hs-Tn was measured using the Architect Stat High Sensitivity Troponin-I (Abbott), Access 2 hsTnI (Beckman Coulter), and Elecsys Troponin T Gen 5 STAT (Roche) assays. hs-Tn below the limit of detection (LOD) is reported as the lower limit of detection (LLOD) Of 63 subjects, 76 % were transgender women. We found no significant difference in median hs-Tn concentrations or proportions of hs-Tn > LOD. In this cohort of stable transgender patients without CHF or CKD, we did not observe differences in hs-Tn concentrations between transgender women and transgender men. Meaningful conclusions are limited owing to inadequate sample size and population differences. Further research on hs-troponin concentrations in this underrepresented, vulnerable population is needed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0009-8981
1873-3492
1873-3492
DOI:10.1016/j.cca.2022.12.003